Viral Vector & Plasmid DNA Manufacturing - Global Market Outlook (2018-2027)

   |      |      |  

Viral Vector & Plasmid DNA Manufacturing - Global Market Outlook (2018-2027)

"The Global Viral Vector & Plasmid DNA Manufacturing market is accounted for $321.60 million in 2018 and is expected to reach $1,178.24 million by 2027 growing at a CAGR of 15.1% during the forecast period. Some of the factors such as raise in alertness regarding gene therapy and raise in funding for R&D performance pertaining to gene therapy are driving the growth of the market. However, high price linked with gene therapies is likely to hamper the market growth.

Viral Vector & Plasmid DNA are commodities of gene therapy, which are used for the dealing of a great number of diseases. The advantages of gene vaccines and therapy in excess of conventional vaccines and therapies include the capacity to bring a wide variety of immune response types. A number of clinical studies are being conducted on this market, which highlight the potential of gene therapy to deal with significant medical needs, and have initiated a surge of savings in drug expansion and commercialization of these therapies.

By vector type, plasmid DNA segment is likely to have a huge demand in the forecast period due to the clinical research applications in gene therapy and genetic vaccination. The command and therapeutic applications for plasmid DNA (pDNA) have fast grown and extended.

On the basis of geography, North America is estimated to have a huge demand owing to the growing investments in gene therapy commodities in the United States in recent years. In the United States, rigid support and patient encouragement have pressed rare illness clinical research to the centre stage.

Some of the key players in Viral Vector & Plasmid DNA Manufacturing Market include Lonza, Catapult, uniQure N.V., FUJIFILM Diosynth Biotechnologies, Kaneka Eurogentec S.A., Oxford Biomedica, Spark Therapeutics, Inc., Cobrabiologics, Merck KGaA, Brammer Bio, Cell and Gene Therapy Catapult, FinVector Vision Therapies, MassBiologics, SIRION Biotech and Thermo Fisher Scientific.

Vector Types Covered:
• Viral Vectors
• Non-Viral Vectors

Workflows Covered:
• Downstream Processing
• Upstream Processing

Diseases Covered:
• Infectious Diseases
• Cancer
• Genetic Disorders

Sales Channels Covered:
• Direct Sales
• Channel Sales

Applications Covered:
• Vaccinology
• Antisense & RNAi, & Molecular Therapy
• Cell Therapy
• Cancer
• Viral Infections
• Gene Therapy
• Inherited Disorders
• Viral Vaccines
• Protein Expression Studies
• Formulation Development

End Users Covered:
• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes
• Immunotherapy
• DNA Vaccines
• Hospitals

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
"

"1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Viral Vector & Plasmid DNA Manufacturing Market, By Vector Type
5.1 Introduction
5.2 Viral Vectors
5.2.1 Lentiviral Vectors
5.2.2 Adenoviral Vectors
5.2.3 Retroviral Vectors
5.2.4 Adeno-Associated Virus (AAV)
5.2.5 Other Viral Vectors
5.2.5.1 Simian Virus
5.2.5.2 Alphavirus
5.2.5.3 Herpes Simplex Virus
5.2.5.4 Sendai Virus
5.2.5.5 Foamy Virus
5.2.5.6 Vaccinia Virus
5.3 Non-Viral Vectors
5.3.1 Plasmid DNA
5.3.2 Liposomes, Lipoplexes and Polyplexes
5.3.3 Oligonucleotides

6 Global Viral Vector & Plasmid DNA Manufacturing Market, By Workflow
6.1 Introduction
6.2 Downstream Processing
6.2.1 Fill-Finish
6.2.2 Purification
6.3 Upstream Processing
6.3.1 Vector Recovery\/Harvesting
6.3.2 Vector Amplification & Expansion

7 Global Viral Vector & Plasmid DNA Manufacturing Market, By Disease
7.1 Introduction
7.2 Infectious Diseases
7.3 Cancer
7.4 Genetic Disorders

8 Global Viral Vector & Plasmid DNA Manufacturing Market, By Sales Channel
8.1 Introduction
8.2 Direct Sales
8.3 Channel Sales

9 Global Viral Vector & Plasmid DNA Manufacturing Market, By Application
9.1 Introduction
9.2 Vaccinology
9.3 Antisense & RNAi, & Molecular Therapy
9.4 Cell Therapy
9.5 Cancer
9.6 Viral Infections
9.7 Gene Therapy
9.8 Inherited Disorders
9.9 Viral Vaccines
9.10 Protein Expression Studies
9.11 Formulation Development

10 Global Viral Vector & Plasmid DNA Manufacturing Market, By End User
10.1 Introduction
10.2 Pharmaceutical and Biopharmaceutical Companies
10.3 Research Institutes
10.4 Immunotherapy
10.5 DNA Vaccines
10.6 Hospitals

11 Global Viral Vector & Plasmid DNA Manufacturing Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa

12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies

13 Company Profiling
13.1 Lonza
13.2 Catapult
13.3 uniQure N.V.
13.4 FUJIFILM Diosynth Biotechnologies
13.5 Kaneka Eurogentec S.A.
13.6 Oxford Biomedica
13.7 Spark Therapeutics, Inc.
13.8 Cobrabiologics
13.9 Merck KGaA
13.10 Brammer Bio
13.11 Cell and Gene Therapy Catapult
13.12 FinVector Vision Therapies
13.13 MassBiologics
13.14 SIRION Biotech
13.15 Thermo Fisher Scientific

List of Tables
Table 1 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Region (2017-2027) ($MN)
Table 2 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vector Type (2017-2027) ($MN)
Table 3 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Viral Vectors (2017-2027) ($MN)
Table 4 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Lentiviral Vectors (2017-2027) ($MN)
Table 5 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Adenoviral Vectors (2017-2027) ($MN)
Table 6 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Retroviral Vectors (2017-2027) ($MN)
Table 7 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Adeno-Associated Virus (AAV) (2017-2027) ($MN)
Table 8 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Other Viral Vectors (2017-2027) ($MN)
Table 9 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Non-Viral Vectors (2017-2027) ($MN)
Table 10 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Plasmid DNA (2017-2027) ($MN)
Table 11 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Liposomes, Lipoplexes and Polyplexes (2017-2027) ($MN)
Table 12 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Oligonucleotides (2017-2027) ($MN)
Table 13 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Workflow (2017-2027) ($MN)
Table 14 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Downstream Processing (2017-2027) ($MN)
Table 15 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Fill-Finish (2017-2027) ($MN)
Table 16 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Purification (2017-2027) ($MN)
Table 17 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Upstream Processing (2017-2027) ($MN)
Table 18 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vector Recovery\/Harvesting (2017-2027) ($MN)
Table 19 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vector Amplification & Expansion (2017-2027) ($MN)
Table 20 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Disease (2017-2027) ($MN)
Table 21 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Infectious Diseases (2017-2027) ($MN)
Table 22 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Cancer (2017-2027) ($MN)
Table 23 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Genetic Disorders (2017-2027) ($MN)
Table 24 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Sales Channel (2017-2027) ($MN)
Table 25 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Direct Sales (2017-2027) ($MN)
Table 26 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Channel Sales (2017-2027) ($MN)
Table 27 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Application (2017-2027) ($MN)
Table 28 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vaccinology (2017-2027) ($MN)
Table 29 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Antisense & RNAi, & Molecular Therapy (2017-2027) ($MN)
Table 30 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Cell Therapy (2017-2027) ($MN)
Table 31 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Cancer (2017-2027) ($MN)
Table 32 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Viral Infections (2017-2027) ($MN)
Table 33 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Gene Therapy (2017-2027) ($MN)
Table 34 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Inherited Disorders (2017-2027) ($MN)
Table 35 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Viral Vaccines (2017-2027) ($MN)
Table 36 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Protein Expression Studies (2017-2027) ($MN)
Table 37 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Formulation Development (2017-2027) ($MN)
Table 38 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By End User (2017-2027) ($MN)
Table 39 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Pharmaceutical and Biopharmaceutical Companies (2017-2027) ($MN)
Table 40 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Research Institutes (2017-2027) ($MN)
Table 41 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Immunotherapy (2017-2027) ($MN)
Table 42 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By DNA Vaccines (2017-2027) ($MN)
Table 43 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Hospitals (2017-2027) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

"

Viral Vector & Plasmid DNA Manufacturing - Global Market Outlook (2018-2027)

.